vs
Side-by-side financial comparison of ServisFirst Bancshares, Inc. (SFBS) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $159.0M, roughly 1.9× ServisFirst Bancshares, Inc.). ServisFirst Bancshares, Inc. runs the higher net margin — 52.2% vs 12.8%, a 39.3% gap on every dollar of revenue. Over the past eight quarters, ServisFirst Bancshares, Inc.'s revenue compounded faster (17.7% CAGR vs 4.2%).
ServisFirst Bancshares, Inc. is a U.S.-based bank holding company operating full-service banking locations primarily across the Southeastern United States. It offers a full suite of commercial banking, consumer banking, wealth management, and mortgage lending services to small and medium-sized businesses, professional clients, and individual consumers.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
SFBS vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $159.0M | $295.9M |
| Net Profit | $83.0M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 52.2% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | 31.2% | 68.3% |
| EPS (diluted) | $1.52 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $159.0M | — | ||
| Q4 25 | $162.2M | $295.9M | ||
| Q3 25 | $136.3M | — | ||
| Q2 25 | $132.1M | $317.0M | ||
| Q1 25 | $131.8M | $316.2M | ||
| Q4 24 | $131.9M | $297.0M | ||
| Q3 24 | $123.7M | $289.5M | ||
| Q2 24 | $114.8M | $306.1M |
| Q1 26 | $83.0M | — | ||
| Q4 25 | $86.4M | $38.0M | ||
| Q3 25 | $65.6M | — | ||
| Q2 25 | $61.4M | $-17.7M | ||
| Q1 25 | $63.2M | $22.6M | ||
| Q4 24 | $65.2M | $34.9M | ||
| Q3 24 | $59.9M | $33.6M | ||
| Q2 24 | $52.1M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 66.3% | 18.4% | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 58.0% | -7.5% | ||
| Q1 25 | 60.0% | 12.2% | ||
| Q4 24 | 60.2% | 16.0% | ||
| Q3 24 | 58.5% | 13.8% | ||
| Q2 24 | 58.0% | 15.0% |
| Q1 26 | 52.2% | — | ||
| Q4 25 | 59.0% | 12.8% | ||
| Q3 25 | 48.1% | — | ||
| Q2 25 | 46.5% | -5.6% | ||
| Q1 25 | 48.0% | 7.1% | ||
| Q4 24 | 52.9% | 11.7% | ||
| Q3 24 | 48.4% | 11.6% | ||
| Q2 24 | 45.4% | 13.3% |
| Q1 26 | $1.52 | — | ||
| Q4 25 | $1.58 | $0.24 | ||
| Q3 25 | $1.20 | — | ||
| Q2 25 | $1.12 | $-0.11 | ||
| Q1 25 | $1.16 | $0.14 | ||
| Q4 24 | $1.19 | $0.22 | ||
| Q3 24 | $1.10 | $0.21 | ||
| Q2 24 | $0.95 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $1.9B | $2.0B |
| Total Assets | $18.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.8B | $2.0B | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.7B | $2.0B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.6B | $2.1B | ||
| Q2 24 | $1.5B | $2.1B |
| Q1 26 | $18.2B | — | ||
| Q4 25 | $17.7B | $2.5B | ||
| Q3 25 | $17.6B | — | ||
| Q2 25 | $17.4B | $2.6B | ||
| Q1 25 | $18.6B | $2.6B | ||
| Q4 24 | $17.4B | $2.7B | ||
| Q3 24 | $16.4B | $2.7B | ||
| Q2 24 | $16.0B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SFBS
| Net Interest Income | $148.1M | 93% |
| Noninterest Income | $10.8M | 7% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
